tribute to OAC underuse. The good news is that targeted education interventions for patients and providers coupled with real-time reporting and feedback have been shown to increase the use of OACs, cutting the gap in undertreatment in half. 9 Interventions improving treatment are especially effective for patients being inappropriately treated with aspirin, which has a strong recommendation to not be used for stroke prevention in the European AF Guidelines. 3 Restarting anticoagulation after an event that required OAC interruption is another major clinical challenge, resulting in long-term underuse of OACs. Only half of patients with a gastrointestinal bleed have their OAC restarted, despite OAC use being associated with lower mortality rate, lower rate of thrombo-embolism, and no higher rates of recurrent gastrointestinal bleeding. 10 Decision analysis modelling demonstrated a benefit for OACs after upper gastrointestinal bleeds for most patients. 11 Similarly, a decision analysis focusing on falls found that although falls are common, especially among the elderly, traumatic falls are uncommon, and the benefits of OACs generally outweigh the risk of falling, with the estimate that a patient would need to fall 295 times a year for the risk of falls to outweigh the benefits of warfarin. 12 Since non-vitamin K antagonists (NOACs) have much lower rates of intracranial haemorrhage (including traumatic intracranial haemorrhage) than vitamin K antagonists (VKAs), the threshold for not using NOACs is even higher. Edoxaban has been shown, compared with warfarin, to be associated with a greater reduction in all-cause mortality and major bleeding among patients at risk for falls relative to the reductions seen in the overall ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial FibrillationThrombolysis In Myocardial Infarction 48) trial population. The clinical implications of this study need to be viewed in the context of several limitations. First, claims data did not allow a direct linkage between anticoagulation status and the traumatic injury event. If a patient had a medication filled within 90 days prior to the traumatic injury, it was assumed that the patient was on an OAC at the time of the event; however, the timing of the last dose of an NOAC before the injury was not known, and international normalized ratio (INR) values before or at the time of the traumatic injury were not known. Secondly, the exact timing of when patients resumed their OACs following the traumatic injury was not known. Given that 97.9% of patients that resumed an OAC after traumatic injury restarted the same OAC they had been taking prior to the event, these patients probably had a supply of their OAC at home, so the timings of subsequent medication fills after the event were probably not representative of the resumption date of OACs. Although the data are supportive of restarting OACs after a traumatic injury, the analysis did not provide insight into the optimal timing of OAC resumption.
Finally, the 1-year absolute risk differences in all-cause mortality for VKA and NOAC resumption (-4.2% and -4.4%, respectively) were meaningfully higher than the absolute risk differences in stroke (-0.6% and -1.2%, respectively). It was unexpected that VKAs only had a 15% relative lower rate of stroke at 1 year, while NOACs had only a 30% relative lower rate of stroke at 1 year, compared with no anticoagulation. Regardless, since OACs would be expected to affect mortality based on decreased stroke, the higher mortality in the non-resumption cohort probably represented some degree of unmeasured confounding.
Providers should note that risk of recurrent traumatic injury was low (1-year standardized absolute risks ranged from 4.0 to 4.4%), while the 1-year standardized absolute risk of stroke or thromboembolism in the non-resumption cohort was similarly 4.0%. This emphasized the importance of resuming an OAC after traumatic injury, as the risk of recurrent traumatic injury was similar to the risk of stroke in a non-anticoagulated population. A multivariable model in the analysis found an increased risk of bleeding with the use of aspirin (HR 1.27, 95% CI 1.03-1.55) and use of non-steroidal antiinflammatory drugs (HR 1.25, 95% CI 1.01-1.55) combined with anticoagulation. As the European AF Guidelines recommend, providers should focus on avoiding these (and other) preventable contributors to bleeding. 3 Although not the focus of the manuscript, underuse of OACs prior to traumatic injury was identified. There were 8365 patients excluded from the analysis due to not taking an OAC at the time of the traumatic injury, and this was 56.3% of the 14 871 patients otherwise not excluded from the study. The CHA 2 DS 2 -VASc scores for the untreated patients were not known, but this traumatic injury population was an older population with the patients on OACs having a median CHA 2 DS 2 -VASc score of 4 (interquartile range 3-5), so it was probably a small minority that did not meet guideline criteria for an OAC. This 56.3% of AF patients who were not treated with an OAC remains consistent with the previously described rates of underuse. 4, 5 The majority of patients did resume an OAC after their traumatic injury, but a substantial minority of patients (22.7%) did not resume an OAC. A portion of non-resumption patients probably had a true contraindication to OACs, but 27.1% of these non-resumption It is gratifying that rates of resuming an OAC after traumatic injury increased over the course of the study. Nonetheless, failure to resume an OAC after various types of bleeding and trauma (Figure 1) , when evidence strongly suggests benefit, is an important factor resulting in preventable AF-related strokes. This study provides supportive evidence that most patients would benefit from resuming an OAC after traumatic injury. Implementation programmes addressing patient-level, provider-level, and system-level barriers have been effective at increasing rates of OAC use. Expansion of implementation programmes should include a focus on ensuring that most patients who have traumatic injury (or other events leading to discontinuation of OACs) resume anticoagulation to prevent stroke.
